Ono Pharma's Cambridge office is facing layoffs, leading to concerns over job security.
Ono Pharma is set to lay off 83 employees at its Cambridge headquarters by June 30. This decision follows economic challenges in the biopharmaceutical industry, despite recent successes like the FDA approval of Romvimza. The layoffs have raised concerns about project impacts and job security as Ono tries to navigate this difficult period.
In a surprising turn of events, Ono Pharma, the U.S. branch of the long-established Japanese pharmaceutical company, is letting go of 83 employees at its Cambridge headquarters. This news comes as part of a Workers Adjustment Retraining Notice that was filed in Massachusetts on April 22, outlining plans for these layoffs to take effect by June 30. It’s a bittersweet moment for a company that has been expanding its presence in the U.S. since its inception here in 2020.
Founded way back in 1717 in Osaka, Japan, Ono Pharmaceuticals has a rich history of medical contributions. Despite its long-standing roots, the company’s journey in the American market is relatively new. In 2020, Ono made its initial foray into the U.S., and by 2021, it had shifted its headquarters from New Jersey to the bustling innovation hub of Cambridge.
Currently, Ono Pharma operates 20 locations across five different countries, including another site in San Francisco, California. The company is known for developing drugs targeting various specialties, notably in oncology, immunology, and neurology. With such a diverse portfolio, Ono has been a relevant player in the biopharmaceutical field. However, like many in the industry, it is not immune to the economic challenges that are surfacing right now.
The upcoming layoffs at Ono Pharma are part of a larger trend in the biopharmaceutical sector, which has seen many companies also cutting back on staff. As the industry faces economic pressures, these layoffs raise concerns about how they might impact ongoing projects and vital clinical trials. With 83 jobs on the line, it’s a potential setback for the company as it works to advance its drug developments.
Another striking difference is that Turalio, developed by Daiichi Sankyo, comes with warnings for hepatotoxicity, while Romvimza does not have such warnings. Ono secured rights to Romvimza through an impressive $2.4 billion acquisition of Deciphera Pharmaceuticals, which is also based in Boston. This step underscores Ono’s commitment to developing innovative treatments, even as they face tough choices regarding workforce reduction.
In the meantime, the anticipation for Romvimza’s availability in the U.S. market mounts, especially after clinical trials showcased a remarkable 40% objective response rate compared to a strikingly low 0% in placebo groups. If all goes well, Romvimza could soon be providing relief for patients in need. As circumstances unfold, both the employees and the broader biopharma community keep a watchful eye.
Boston Life Sciences Real Estate Market in Turmoil
Thermo Fisher Scientific Cuts 300 Jobs in Massachusetts
CVS Health Shuts Down Accountable Care Business in Wellesley, Job Losses Expected
Massachusetts Job Uncertainty as Bristol Myers Squibb Cuts Costs
Massachusetts Cannabis Industry Faces Tough Times
News Summary Eastern Bankshares, Inc. and HarborOne Bancorp, Inc. have announced a definitive merger agreement…
News Summary President Donald Trump has successfully raised nearly $4.1 million from donors and businesses…
News Summary A Massachusetts Senate committee, led by Senator Mark Montigny, is investigating the South…
News Summary Russell and Linda Callahan have been charged with multiple felonies related to a…
News Summary A recent report by the Institute for Policy Studies reveals a substantial 38.6%…
News Summary In Massachusetts, initial unemployment claims dropped to 4,804 for the week ending April…